Market Trends of Europe Pharmaceutical Glass Packaging Industry
Germany is Expected to Have a Significant Share in the Market
- Germany stands out as one of the global leaders in pharmaceutical and life sciences. It boasts one of Europe's largest pharmaceutical markets, hosts numerous industry frontrunners, nurtures a burgeoning biotech landscape, and operates a robust public healthcare system. Responding to the surging global demand for personalized medicine, Germany emerged as a critical player in producing cutting-edge biopharmaceuticals.
- The demand for pharmaceuticals in Germany is intricately tied to its shifting demographics. With a progressively aging population, there's a heightened need for medical interventions, especially in managing chronic and mobility-related ailments. While these demographic shifts present opportunities for niche and generic drug manufacturers, the stringent regulatory environment in Germany is compelling the pharmaceutical sector to recalibrate pricing strategies, ensuring broader market accessibility.
- The German government is discussing a new Pharma Strategy with several reforms to enhance the conditions for the pharmaceutical industry in Germany. Recently, in Strategy Paper 4.0 - Improving the General Conditions for the Pharmaceutical Sector in Germany, the government is strengthening pharmaceutical research and production to enhance market access and pricing.
- These initiatives are poised to resonate across the life sciences sector, vowing faster clinical trial approvals, swifter access to cutting-edge medicines, heightened digitalization, bolstered supply security, an environment more conducive to investments, and a streamlined bureaucracy. Also, according to Statistisches Bundesamt, the revenue of wholesale pharmaceutical goods in Germany is expected to reach USD 220.34 billion in 2024, and it has increased from USD 209.2 billion in 2021. An increase in revenue from pharmaceutical goods would leverage the glass packaging.
- Additionally, Bayer is developing the Solida-1 pharmaceutical facility in Leverkusen, Germany, to produce solid pharmaceutical products. The company invested EUR 275 million (USD 286.98 million) in the facility. Construction of the facility began in 2020, and a topping-up ceremony was held in May 2022. The facility is expected to start operations in 2024. The Solida-1 facility will be the world's most modern pharmaceutical plant, focusing on producing drugs for cancer and cardiovascular diseases.
Understand The Key Trends Shaping This Market
Download PDF
Growing Traction of Pharmaceutical Glass Packaging in the Region
- The European pharmaceutical glass industry is known for its innovation and research and is a crucial driver of growth in the region. With billions allocated to R&D and a substantial workforce dedicated to these endeavors, the UK is actively bolstering its pharmaceutical pipeline. This presents a lucrative opportunity for glass vial and ampoule vendors.
- Moreover, as the pharmaceutical market expands, so does the region's demand for pharmaceutical glass packaging. Players introduce a variety of glass packaging products, including ampoules, vials, and syringes, and they scale up their manufacturing capabilities and product portfolios.
- The government's focus on ensuring access to innovative medicines may lead to increased research and development activities in the pharmaceutical sector. This could result in the development of new and advanced pharmaceutical packaging solutions, including glass vials and ampoules with improved features to meet the industry's evolving needs.
- The French government's plan to restore the production of essential medicines as part of its broader effort to ensure access to a wide range of products, including pharmaceuticals and medical devices, can have several implications for the pharmaceutical glass packaging market in France.
- In June 2023, the French government announced its reshoring plan to restructure the production of critical medicines. Reshoring is part of a more significant effort to ensure patient access to all medical products, including new drugs and equipment, and the 'established or older products that may be adversely affected by future shortages. Reshoring the production of essential medicines implies an increased focus on domestic manufacturing. This could lead to a rise in demand for packaging materials, including pharmaceutical glass vials and ampoules, to accommodate the increased production of medicines.
- Moreover, the market is expected to grow with a focus on developing new medicines. According to EFPIA, the number of drugs approved by the EMA available to patients, Germany took the top position with 147 approved medicines in 2023, followed by Italy, Austria, and other countries. An increase in medications might propel glass packaging in the pharmaceutical sector across the region.
Get Analysis on Important Geographic Markets
Download PDF
